[
  {
    "ts": null,
    "headline": "Why Analysts See the Prologis Story Shifting Amid New Developments and Mixed Market Signals",
    "summary": "Recent changes to Prologis's fair value estimate highlight evolving sentiment in the industrial real estate sector. The fair value estimate for the company has increased slightly to $121.45 from $120. This reflects newly updated analysis of sector fundamentals and increased optimism about demand. Stay tuned to discover how you can continue tracking shifts in the Prologis narrative as market conditions develop. What Wall Street Has Been Saying Recent analyst reports on Prologis reflect a mix...",
    "url": "https://finnhub.io/api/news?id=758c9acdfc922750ec25eea50eb37e09e35033f674b650f3f517fa6c959e740e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760180922,
      "headline": "Why Analysts See the Prologis Story Shifting Amid New Developments and Mixed Market Signals",
      "id": 137049257,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PLD",
      "source": "Yahoo",
      "summary": "Recent changes to Prologis's fair value estimate highlight evolving sentiment in the industrial real estate sector. The fair value estimate for the company has increased slightly to $121.45 from $120. This reflects newly updated analysis of sector fundamentals and increased optimism about demand. Stay tuned to discover how you can continue tracking shifts in the Prologis narrative as market conditions develop. What Wall Street Has Been Saying Recent analyst reports on Prologis reflect a mix...",
      "url": "https://finnhub.io/api/news?id=758c9acdfc922750ec25eea50eb37e09e35033f674b650f3f517fa6c959e740e"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.",
    "summary": "Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswing.",
    "url": "https://finnhub.io/api/news?id=0c37777d4a658fa4dcbd69eea2e7456da295d35bc8206da0a75f130d74302ed7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760141880,
      "headline": "Biotech Stocks Have Struggled Since 2021. Why They’re Coming Back.",
      "id": 137049056,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PLD",
      "source": "Yahoo",
      "summary": "Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswing.",
      "url": "https://finnhub.io/api/news?id=0c37777d4a658fa4dcbd69eea2e7456da295d35bc8206da0a75f130d74302ed7"
    }
  }
]